

DAFTAR PUSTAKA

- American Heart Association. 2010. *Cardiovascular Disease Statistics*, (online) (<http://www.americanheart.org/presenter.jhtml?identifier=4591>, diakses 18 Desember 2014)
- American Heart Association. 2013. *Atherosclerosis*. (online). (http://www.heart.org/HEARTORG/Conditions/Cholesterol/WhyCholesterolMatters/Atherosclerosis_UCM_305564_Article.jsp, diakses pada tanggal 12 Januari 2014)
- Anitra C, McCall, Frei B. 2000. Oxidation of LDL by Myeloperoxidase and Reactive Nitrogen Species : Reaction Pathways and Antioxidant Protection. *American Heart Association*, Vol. 20:1716-1723
- Beckman, Joshua A. 2002. Diabetes and Atherosclerosis : Epidemiology, Pathophysiology, and management, *Journal of American Medical Association*. v287 no.19 p2570-2581
- Bhatia V.K. 2007. Complement C1q Reduces Early Atherosclerosis in Low-Density Lipoprotein Receptor Deficient Mice. *The American Journal of Pathology*, Vol. 170 No. 1
- Boudi, F.B. 2014. *Atherosclerosis*, (online) (<http://emedicine.medscape.com/cardiology#atherosclerosis>, diakses 18 Desember 2014)
- Brentjens, R and Saltz, L. 2001. Islet cell tumors of the pancreas: the medical oncologist's perspective. *Surg Clin North Am*. 81(3):527-42.
- Cooke DW, Plotnick L. 2008. "Type 1 diabetes mellitus in pediatrics". *Pediatr Rev* 29 (11): 374–84; quiz 385
- Faulin, TES, Garcia MCC, Abdalla DSP. 2009. Recent Advances on Detection of Modified Forms of Low-Density Lipoproteins. *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery*. 3: 28-34.
- Ferrannini E. 2010. The stunned beta cell: a brief history. *Cell Metab*. 11, 349–352.10.1016/j.cmet.2010.04.009
- Guyton, John R. 2003. *ATHEROSCLEROSIS – A STORY OF CELLS, CHOLESTEROL, AND CLOTS*. (Offline). (<http://classes.biology.ucsd.edu/bisp194-2.W111/Guyton%20article.pdf>, diakses pada tanggal 12 Januari 2014)
- Hansson, G. K. 2005. Inflammation, Atherosclerosis, and Coronary Artery Disease. *NewEngland Journal of Medicine*. 352:1685-95
- Hartree, N., Tidy, C. dan Bonsall, A. 2013. *Atherosclerosis*. (online). (<http://www.patient.co.uk/doctor/atherosclerosis>, diakses pada tanggal 13 Januari 2013)
- Itabe H. (2003). Oxidized Low-Density Lipoproteins: What is Understood and What

Remains to Be Clarified. *Biol Pharm Bull.* 26(1): 1-9

Kannel, William. 2009. *Cardiovascular Disease Risk Assessment*. (Online). ([http://www.athero.org/pdf/Highlights_RiskFactors_WebPost .pdf](http://www.athero.org/pdf/Highlights_RiskFactors_WebPost.pdf), diakses pada tanggal 12 Januari 2014)

Kearney, J.F. 2000. Immune recognition of OxLDL in atherosclerosis. *The Journal of Clinical Investigation*, Vol.105 No.12

Khardori, Romesh. 2014. Diabetes Mellitus type 2. (online) (<http://emedicine.medscape.com/article/117853-overview#aw2aab6b2b3> diakses pada tanggal 18 Januari 2015)

Ladich, Elena R. 2012. Atherosclerosis Pathology. (online) (<http://reference.medscape.com/article/1612610-overview#aw2aab6b4> diakses pada tanggal 18 Desember 2014)

Longo, Dan L, Dennis, L.Kasper, Fauci, Anthony S, et. al. 2012. *Harrison's Principles of Internal Medicine 18th Edition*. US: Mc Graw Hill Company. Vol:1

Ludewig. 2004. Immunopathogenesis of Atherosclerosis. *Journal of Leucocyte Biology*, Vol. 76

McGill HC. 2000. Origin of atherosclerosis in childhood and adolescence. *American Journal of Clinical Nutrition*, Vol. 72 : 1307-1315

Mohler, E.R. 2008. The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart disease or Coronary Heart Disease Risk Equivalent. *Journal of the American college of Cardiology*. Vol 51 : p1632-1642

Nobeyba, Ortega R. 2012. *Atherosclerosis Pathology*. (Online). (<http://www.lahc.edu/classes/nursing/Atherosclerosis%20Pathology.pdf>, diakses pada tanggal 13 Januari 2014)

Oskjoki, Riina. 2006. *Immune Mechanism in atherosclerosis : Focus on the Role of Complement System*. Helsinki.

Prasetyo, Awal and Sadhana, Udadi. 2006. *ASPEK SELULER DAN MOLEKULER ATEROSKLEROSIS*. Media Medika Muda (M3) (2). ISSN 1858-3318

Rosenson, R.S. & Stafforini, D.M., 2000. Modulation of oxidative stress , inflammation , and atherosclerosis by lipoprotein-associated phospholipase A 2 Address for correspondence : , pp.1-34

Sertić, J. 2010. Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?. *Acta Med Croatia* 64 (4):237-45

Serruys, Pattrick W. 2008. Effects of the Direct Lipoprotein-Associated phospholipase A₂ Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. *Circulation*. 2008; 118: 1172-1182

Su, Jun. 2009. *Natural Antibodies Against Phosphorylcholine as Potential Protective Factors in Atherosclerosis, Cardiovascular Disease and Systemic Lupus Erythematosus*. Stockholm

Stoffers D. A. 2004. The development of beta-cell mass: recent progress and potential role of GLP-1. *Horm Metab Res* 36, 811–82110.1055/s-2004-826168

Talchai C., Xuan S., Lin H. V., Sussel L., Accili D. 2012. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. *Cell* 150, 1223–123410.1016/j.cell.2012.07.029

Tsimikas. 2005. Oxidized Phospholipid, Lp(a) Lipoprotein, And Coronary Artery Disease. *New England Journal of Medicine*, 2005. v353:46-57.

US Census Bureau. 2004. *Statistics by Country for Atherosclerosis*, (online) (<http://www.cureresearch.com/statistics.htm>, diakses 12 Agustus 2010)

WHO official. 2012. Diabetes Mellitus. (online) (www.who.int/diabetes.com diakses tanggal 21 oktober 2014 pukul 21.00)

WHO. 2013. *10 facts on noncommunicable disease*. (Online). (http://www.who.int/features/factfiles/noncommunicable_diseases/en/index.html, diakses pada tanggal 13 Januari 2014)

WHO official. 2014. Diabetes. (online) (<http://www.who.int/mediacentre/factsheets/fs312/en/>) diakses tanggal 7 Januari 2015 pukul 06.30

World Health Organization. 1999. *Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications*. Geneva: Departemen of Noncommunicable Disease Surveillance.

Zalewski, A. & Macphee, C., 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 25, pp.923–931.